Equities

Qinghai Spring Medicinal Resources Technology Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Qinghai Spring Medicinal Resources Technology Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)2.99
  • Today's Change0.14 / 4.91%
  • Shares traded12.43m
  • 1 Year change-25.06%
  • Beta0.0429
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Qinghai Spring Medicinal Resources Technology Co Ltd is a China-based company principally engaged in the beverage and fast-moving consumer goods business and the health and wellness business. The Company operates its businesses through three segments. The Health and Wellness segment is primarily engaged in the research, development, production, and sale of Cordyceps sinensis products. The Beverage and Fast-Moving Consumer Goods segment is primarily engaged in the sale of beverages and other consumer goods. The Advertising Agency segment is primarily engaged in advertising agency and publishing services. The Company mainly conducts its business in the domestic market.

  • Revenue in CNY (TTM)284.76m
  • Net income in CNY-111.15m
  • Incorporated1998
  • Employees159.00
  • Location
    Qinghai Spring Medicinal Resources Technology Co Ltd16F, Ningjing Business CenterXINING 810003ChinaCHN
  • Phone+86 9 718816171
  • Fax+86 9 718816171
  • Websitehttps://www.verygrass.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Qinghai Spring Medicinl Rsrcs Tech CoLTD284.76m-111.15m1.67bn159.00--1.62--5.88-0.1864-0.18640.4961.750.24921.084.071,790,944.00-9.61-15.06-10.10-15.6631.0122.84-38.56-147.188.94-2.610.0045--26.362.9525.80---1.38--
Hunan Nucien Pharmaceutical Co Ltd119.87m-353.70m2.32bn360.00--2.68--19.34-1.28-1.280.43623.160.09981.410.4888---32.50-5.94-36.98-8.1932.4183.51-325.67-15.022.29-139.490.1562---64.64-23.64-9,613.65--35.48--
Shaanxi Kanghui Pharmaceutical Co Ltd513.23m-183.84m2.35bn906.00--3.24--4.57-1.84-1.845.147.260.26361.932.53566,479.70-11.36-1.99-18.19-2.6924.4636.16-43.08-6.590.5483-2.100.4726---16.545.42-242.62---10.54--
Hangzhou Tianmushan Phrmtcl ntrprs C Ltd251.56m33.15m2.38bn362.0071.7335.71--9.450.27230.27232.070.54680.6322.972.32694,905.808.32-8.8427.42-25.8047.9332.1713.17-21.830.6559.230.648--78.44-6.06139.83-21.36-26.32--
Zhejiang East Asia Pharmaceutical Co Ltd831.56m-218.24m2.47bn1.75k--1.36--2.96-1.97-1.977.3415.800.24090.86345.60475,447.80-6.332.47-8.093.1225.7824.66-26.255.780.7513-411.460.353342.92-11.663.93-183.02--29.64--
Jiangsu gdk Biotechnology Co Ltd116.56m-126.51m2.47bn452.00--2.07--21.17-1.03-1.030.94619.670.07750.73221.14257,878.40-8.421.65-9.842.1460.8073.17-108.547.561.83--0.046553.80-39.963.77-31.71--12.74--
Data as of Feb 06 2026. Currency figures normalised to Qinghai Spring Medicinal Resources Technology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.